
Glaukos (GKOS) Stock Forecast & Price Target
Glaukos (GKOS) Analyst Ratings
Bulls say
Glaukos Corp has demonstrated significant improvement in operational efficiency, with an operating margin of (17.3%), a substantial increase of 2,200 basis points year-over-year, exceeding consensus expectations. The company's innovative iDose product contributed to sequential revenue growth of approximately $16 million, with projected sales of $115-120 million by 2025, highlighting its potential for future revenue expansion. Furthermore, Glaukos reported glaucoma revenues of $84 million, which surpassed consensus estimates and grew by 39% year-over-year, reflecting strong domestic and international performance, thereby positioning the company favorably for profitability in the coming years.
Bears say
Glaukos Corp reported Corneal Health revenue of $21 million, which fell short of the consensus estimate of $22 million and reflected a slowdown in growth to 2%, down from 5% in the previous quarter. The company faces significant risks, including poor sales execution, an increasingly competitive market for minimally invasive glaucoma surgery (MIGS), and reimbursement challenges, which could hinder future revenue performance. Additionally, while the gross margin decreased to 82.3%, just below expectations, substantial reductions in selling, general, and administrative expenses (SG&A) and research and development (R&D) expenses did not offset the negative growth trends and competitive pressures the company is encountering.
This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.
Glaukos (GKOS) Analyst Forecast & Price Prediction
Start investing in Glaukos (GKOS)
Order type
Buy in
Order amount
Est. shares
0 shares